Table 5.
Compound ranking score for cancer research investment against 2013 global disease burdens, across mortality, years lived with disability (YLDs) and disability-adjusted life years (DALYs), by cancer site
| Disease | Research investment (UK pound) by burden observed, 2013 |
|||
|---|---|---|---|---|
| Mean ranking across all burden metrics | Mortality | Years lived with disability | Disability-adjusted life years | |
| Prostate | 2.7 | 2 | 4 | 2 |
| Ovarian | 3.0 | 4 | 2 | 3 |
| Mesothelioma | 4.0 | 6 | 1 | 5 |
| Breast | 4.0 | 3 | 5 | 4 |
| Testicular | 4.7 | 1 | 3 | 10 |
| Skin | 5.0 | 5 | 9 | 1 |
| Colorectal | 6.7 | 7 | 7 | 6 |
| Renal | 8.3 | 8 | 10 | 7 |
| Cervical | 9.7 | 9 | 12 | 8 |
| Pancreatic | 10.0 | 12 | 6 | 12 |
| Brain | 11.0 | 11 | 11 | 11 |
| Thyroid | 11.3 | 10 | 15 | 9 |
| Liver | 11.3 | 13 | 8 | 13 |
| Lung | 13.7 | 14 | 13 | 14 |
| Upper GI | 14.7 | 15 | 14 | 15 |
| Bladder | 16.0 | 16 | 16 | 16 |
GI, gastrointestinal